Related Experiment Video

Updated: Jun 28, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.3K

Molecular mechanism and intervention measures of microvascular complications in diabetes

Rui Xu1, Ziming Fang2, Hongyu Wang3

  • 1Hanan Branch of the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.

Open Medicine (Warsaw, Poland)
|April 22, 2024
PubMed
Abstract

Insights

Preventing diabetic microvascular complications like nephropathy and retinopathy is crucial, as current treatments offer no breakthroughs. Early intervention and risk factor management are key for better patient outcomes in diabetes care.

Area of Science:

  • Endocrinology and Metabolism
  • Diabetology

Background:

  • Diabetic microvascular complications, including nephropathy, retinopathy, and neuropathy, significantly impact patient health.
  • Understanding the epidemiology and molecular mechanisms is vital for managing diabetes.

Purpose of the Study:

  • To review the epidemiology, pathogenesis, risk factors, and treatments of diabetic microvascular complications.
  • To provide a theoretical basis for improved understanding and management of these conditions.

Main Methods:

  • A systematic literature search was conducted on the PubMed electronic database.
  • Eligibility screening, data extraction, and quality assessment were performed by independent reviewers.

Main Results:

  • Thirty-eight articles were included in the review.
  • Diabetic nephropathy, retinopathy, and peripheral neuropathy are common serious complications.
  • Certain drug classes (e.g., RAS blockers, statins, anti-VEGF) show potential in inhibiting complication development.

Conclusions:

  • Current treatments for diabetic microvascular complications have not yielded significant breakthroughs.
  • Prevention strategies are paramount and more critical than treatment for managing diabetic microvascular complications.
Keywords:
epidemiologymicrovascular complicationmolecular mechanismrisk factorstreatment

More Related Videos

Laser Doppler: A Tool for Measuring Pancreatic Islet Microvascular Vasomotion In Vivo10:39

Laser Doppler: A Tool for Measuring Pancreatic Islet Microvascular Vasomotion In Vivo

Published on: March 8, 2018

8.3K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.8K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
275
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
528
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
924
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
174